期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗肿瘤药物临床研究进展 被引量：1

Advances in clinical research of anticancer drugs
下载PDF
导出
摘要 近年来抗肿瘤药物的研究取得了飞速发展,使得肿瘤的治疗有了新的突破.随着分子生物学的发展,人们对肿瘤的认识不断深入,以及高通量筛选、计算机辅助设计、基因工程等新技术的应用,使得抗肿瘤药物的研究水平不断提高,在传统的抗肿瘤药物发展的同时,出现了一些新型的抗肿瘤药物,作用于肿瘤发生和转移的不同环节和新靶点.本文将对近年来临床抗肿瘤药物研究的一些热点作一综述.
作者 汤致强 戴媛媛
机构地区 中国医学科学院肿瘤医院
出处 《临床药物治疗杂志》 2005年第2期5-7,共3页 Clinical Medication Journal
关键词 抗肿瘤药物 临床研究进展 治疗 新靶点 肿瘤发生 高通量筛选 分子生物学 发展 突破 热点
分类号 R979.1 [医药卫生—药品] R730.54 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1[1]Herbst RS,Hess KR.Tran HT,et al.Phase I study of re combinant human endostatin in patients with advanced solid tumors.J Clin Onco,2002,20(18):3792～3803
  • 2[2]Thomas JP,Arzoomanian RZ,A1berti D,et al.Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced so1id tumors.J Clin Onco,2003,21(2):223～231
  • 3[3]Gingras D,Boivin D,Deckers C,et al.Neovasta tanovel antiangiogenic drug for cancer therapy.Anti Cancer Drugs,2003,l4(2):91～96
  • 4[4]Falardeau P,Champagne P, et al.Nevoastat,a natural lyoccurring multifunction,antiangiogenic drug in phase Ⅲ clinical trials.Semin Oncol,2001,28(6):620～625
  • 5[5]Cunningham D,Humblet Y,Siena S,et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer.N Engl J Med,2004,351:337～345
  • 6[6]Fukuoka M,Yano S,Giaccone G,et al.Multi-institu tional randomised phase II trial of gefitinib for previously treated patients with advanced non sma1l cell lung cancer.J Clin Onco,2003,21:2237～2246
  • 7[7]Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: A phase Ⅲ trial- INTACT 1. J Clin Onco,2004,22:777～784
  • 8[8]Herbst RS,Giaccone C,Schiller JH,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer;A Phase Ⅲ trial-INTACT2.J Clin Onco,2004,22:785～794
  • 9[9]Herbst RS Er1otinib(Tarceva):An update on the clinical trial program.Semin Onco 2003,30(Suppl.7):S34～S46
  • 10[10]Schiller JH,New Directions In the treatment of solid tumors.Semin Onco.2003,30(suppl),S49～S55

同被引文献30

  • 1Liu JS, Kuo SR, Mchugh MM, et al. Adozelesin triggers DNA damage response pathways and arrests SV40 DNA replication though replication protein A inactivation[J]. J Biol Chem, 2000, 275(2): 1 391- 1 397.
  • 2Awada A, Punt C J, Piccat M J, et al. Phase I study of Carzelesin (U- 80, 244) given (4-weekly) by intravenous bolus schedule[J]. Br J Cancer, 1999, 79(9 - 10): 1 454 - 1 461.
  • 3Van Custsem E, Cunningham D, Maruun J, et al. Raltitrexed: current clinical status and future directions[J]. Ann Oncol, 2002, 13(4): 513- 522.
  • 4Diaz- Rubio E. New chemotherapeutic advances in pancreatic, coloreetal, and gastric cancers [ J ]. Oncologist, 2004, 9 (3): 282 - 294.
  • 5Vogelzang N J, Rusthoven J J, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J]. J Clin Oncol, 2003, 21(14): 2 636 -2 644.
  • 6Baker DE. Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the conlon or rectum[J]. Rev Gastroenterol Disord, 2003, 3 (1):31 -38.
  • 7Countinho AK, Rocha LCM. Metastatic colorectal cancer: systemic treatment in the new millennium[J].Cancer Control, 2003, 10(3): 224- 238.
  • 8Hartmann JT, Lipp HP. Toxicity of paltinum compounds[J] .Expert Opin Pharmacother, 2003, 4 (6) : 889 - 901.
  • 9Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity[J]. Ann Oncol, 2002, 13(12): 1 841 - 1 851.
  • 10Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancel[J ]. Oncologist, 2002, 7 (Suppl 5): 29 - 35.

引证文献1

二级引证文献2

临床药物治疗杂志
2005年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部